Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL

Competing interests

R.T.M. has acted as a consultant and/or adviser of Artiva Therapeutics, Bristol-Myers Squibb/Celgene, CRISPR Therapeutics, Incyte, Kite and Novartis and has received research funding from BMS and Novartis. J.G. has acted as a consultant and/or adviser of Janssen, Kite Pharma, Legend Biotech and MorphoSys and has received research funding from Angiocrine Bioscience, Celgene (a BMS company), Juno Therapeutics (a BMS company) and Sobi.

留言 (0)

沒有登入
gif